Synthesis and application of microbubble-forming compounds
The present disclosure is directed to fatty-acid glycerol ester derivative compounds containing a targeting bisphosphonate group. The disclosure further include pharmaceutical or biomedical compositions comprising these compounds, and methods of using these compounds and compositions forming microbubbles. The microbubbles have affinity for metal-containing, especially calcium-containing, bodies and/or biological targets. In certain embodiments, these compositions are useful for providing targeted placement of microbubbles capable of cavitation on application of high frequency energy.
1. A pharmaceutical or biomedical composition comprising one or more compounds of the formula selected from the group consisting of formula (I), formula (Ia), formula (II), formula (III), formula (IV) and formula (V):
wherein:
each n is independently selected from 0-7;
each m is independently selected from 0-26;
each p is independently selected from 7-26;
each q is independently selected from 1-90;
each R 1 is independently selected from the group consisting of: hydrogen, C 1 -C 26 alkyl, C 1 -C 26 substituted alkyl, C 1 -C 26 alkenyl, C 1 -C 26 substituted alkenyl, C 1 -C 26 alkynyl, C 1 -C 26 substituted alkynyl, C 1 -C 26 alkyl aryl, C 1 -C 26 substituted alkyl aryl, C 1 -C 26 alkenyl aryl, C 1 -C 26 substituted alkenyl aryl, C 1 -C 26 alkynyl aryl, C 1 -C 26 substituted alkynyl aryl;
each R 2 is independently selected from the group consisting of: hydrogen, C 1 -C 26 alkyl, C 1 -C 26 substituted alkyl, C 1 -C 26 alkenyl, C 1 -C 26 substituted alkenyl, C 1 -C 26 alkynyl, C 1 -C 26 substituted alkynyl, C 1 -C 26 alkyl aryl, C 1 -C 26 substituted alkyl aryl, C 1 -C 26 alkenyl aryl, C 1 -C 26 substituted alkenyl aryl, C 1 -C 26 alkynyl aryl, C 1 -C 26 substituted alkynyl aryl, C 3 -C 8 cycloalkyl, C 3 -C 8 substituted cycloalkyl, C 3 -C 8 aryl, C 3 -C 8 substituted aryl, C 3 -C 8 heterocycloalkyl, C 3 -C 8 substituted heterocycloalkyl, C 3 -C 8 heteroaryl, C 3 -C 8 substituted heteroaryl, acyl, aminoacyl, thioacyl, aminocarbonyl, aminoacyl carbonyloxy, aminothiocarbonyl, aminosulfonyl, amidino, substituted sulfonyl, substituted sulfinyl, carboxy ester, phthalimido, SO 3 H and PO 3 H;
C is selected from the group consisting of:
B is selected from the group consisting of: a covalent bond, ethylene glycol, and polyethylene glycol;
A is selected from the group consisting of: a covalent bond, acyl, acylamino, aminoacyl, acyloxy, thioacyl, aminocarbonyl, aminoacyl carbonyloxy, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyloxy, aminosulfonylamino, aminosulfonyl, amidino, and carboxy ester, wherein any of these functional groups listed for A may be covalently bonded on either side to the
moiety;
Y is selected from the group consisting of: a covalent bond, acyl, acylamino, aminoacyl, acyloxy, thioacyl, aminocarbonyl, aminoacyl carbonyloxy, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyloxy, aminosulfonylamino, aminosulfonyl, amidino, and carboxy ester, wherein any of these functional groups listed for A may be covalently bonded on either side to either one of the
moieties;
X is selected from the group consisting of: hydrogen, silyl, acyl, aminoacyl, thioacyl, aminocarbonyl, aminoacyl carbonyloxy, aminothiocarbonyl, aminosulfonyl, amidino, substituted sulfonyl, substituted sulfinyl, carboxy ester, phthalimido, SO 3 H and PO 3 H;
W is selected from the group consisting of: O, NR 2 , and S;
Z is selected from the group consisting of: a covalent bond, CH 2 , O, NR 2 , and S;
M is selected from the group consisting of: a covalent bond, CH 2 —CH 2 , CH 2 —CH 2 —Z, CH 2 —Z and CH 2 ;
or a tautomer and/or a pharmaceutically acceptable salt thereof.
2. The pharmaceutical or biomedical composition of claim 1 , wherein the composition is a suspension, a colloid, an emulsion, an aerosol, a sol, a gel, a foam, or in the form of microbubbles.
3. The pharmaceutical or biomedical composition of claim 2 , wherein the composition is in the form of microbubbles having a diameter of about 1 micron to about 10 microns, optionally wherein the microbubbles have an affinity for metal-containing material.
4. The pharmaceutical or biomedical composition of claim 2 , wherein the composition is in the form of microbubbles, the microbubbles comprising a core containing a fluid having a normal boiling point less than about 30° C., optionally wherein the fluid is air, CO 2 , a fluorinated C 1-6 hydrocarbon, or any combination thereof.
5. The pharmaceutical or biomedical composition of claim 4 , wherein the fluid is a fluorinated C 1-6 hydrocarbon and wherein the fluorinated C 1-6 hydrocarbon is perfluoropropane or perfluoropentane.
6. The pharmaceutical or biomedical composition of claim 1 , wherein the composition further comprises one or more pharmaceutically acceptable excipients.
7. The pharmaceutical or biomedical composition of claim 6 , wherein the composition comprises sterilized water or a sterilized physiological fluid.
8. The pharmaceutical or biomedical composition of claim 2 , wherein the composition is in the form of microbubbles, and wherein the microbubbles have a diameter of about 1 micron to about 10 microns.
9. The pharmaceutical or biomedical composition of claim 1 , wherein the compound of Formula V is selected from: